IP Library Granted Patent US 11,059,789
Granted Patent B2
US 11,059,789 · App. 16/557,779 · Granted Jul 13, 2021

Isoquinoline-steroid conjugates and uses thereof

Inventors: Mitchell A. deLong (Chapel Hill, NC); Eric Carlson (Irvine, CA); Casey Kopczynski (Chapel Hill, NC); Jill M. Sturdivant (Chapel Hill, NC); Cynthia Lichorowic (Raleigh, NC)
Assignee: Aerie Pharmaceuticals, Inc.
C07D217/22A61K47/28A61K9/0048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,059,789
App. No.
16/557,779
Granted
Jul 13, 2021
Kind
B2
Abstract

Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.

Claims (92)

1. A compound selected from:

or a pharmaceutically acceptable salt thereof.

2. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein R 8 is

R 10 is

 and R 11 is

3. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

4. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

5. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

6. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

7. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

8. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

9. A compound having the formula:

R 8 —R 10 -R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

10. A compound having the formula:

R 8 —R 10 —R 11

or a pharmaceutically acceptable salt thereof,

wherein

R 8 is

R 10 is

 and

R 11 is

11. A composition, comprising the compound of claim 1 .

12. A composition, comprising the compound of claim 2 .

13. A composition, comprising the compound of claim 3 .

14. A composition, comprising the compound of claim 4 .

15. A composition, comprising the compound of claim 5 .

16. A composition, comprising the compound of claim 6 .

17. A composition, comprising the compound of claim 7 .

18. A composition, comprising the compound of claim 8 .

19. A composition, comprising the compound of claim 9 .

20. A composition, comprising the compound of claim 10 .

21. A pharmaceutical composition, comprising the compound of claim 1 , and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition, comprising the compound of claim 2 , and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition, comprising the compound of claim 3 , and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition, comprising the compound of claim 4 , and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition, comprising the compound of claim 5 , and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition, comprising the compound of claim 6 , and a pharmaceutically acceptable carrier.

27. A pharmaceutical composition, comprising the compound of claim 7 , and a pharmaceutically acceptable carrier.

28. A pharmaceutical composition, comprising the compound of claim 8 , and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition, comprising the compound of claim 9 , and a pharmaceutically acceptable carrier.

30. A pharmaceutical composition, comprising the compound of claim 10 , and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2024
From: AERIE PHARMACEUTICALS, INC.
To: ALCON INC.
Reel/Frame 067822/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2019
From: DELONG, MITCHELL A.; CARLSON, ERIC; KOPCZYNSKI, CASEY; STURDIVANT, JILL M.; LICHOROWIC, CYNTHIA
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 050227/0169 →